back to news
CSRO Responds to RFI Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Posted: July 16, 2018
The Coalition of State Rheumatology Organization’s (CSRO) has submitted their comments regarding the Request for Information (RFI) by the Department of Health and Human Services. The request was made after the President issued his “Blueprint to Lower Drug Prices” back in early May.
The Department of Health and Human Services has been requesting meetings with drug manufacturers and pharmacy benefit managers to discuss changes to the system. It is expected that the Center for Medicare and Medicaid Innovation (CMMI) will release a Rule in response to the feedback gathered from the RFI and meetings with stakeholders within the next couple of months.
In preparation, the CSRO has been gathering feedback from the rheumatology community and its patient organizations.
CSRO RFI Response Highlights:
Read Full Comments
- Part B Competitive Acquisition Program
- Moving drugs from Part B to Part D
- Reducing the impact of manufacturer rebates to Pharmacy Benefit Managers
- Copay discount cards
- Incentives to lower or not increase list prices
- Fiduciary duty for Pharmacy Benefit Managers
- Federal Preemption of Pharmacy Gag Clause Laws